Kein-Leong Yim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kein-Leong Yim has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
A. Christian
University Hospital Wales
1 shared publicationA. E. Quinton
Wales Cancer Research Centre, Cardiff, UK
1 shared publicationB. M. Thomas
Velindre Cancer Centre
1 shared publication- David Cunningham
The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research Biomedical Research Centre, London, United Kingdom
1 shared publication Harry Kellam
University of Cardiff, Cardiff, CF10 3AT UK
1 shared publicationKellam Harry
University of Cardiff, Cardiff, CF10 3AT UK
1 shared publication
Latest Publications
- 2 September 2019
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 19 (1) , 661
Correction to: Exploring the bi-directional relationship between pancreatic cancer and diabetes mellitus: a retrospective study
Please note, we are currently updating the 2018 Journal Metrics. Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of diabetes and endocrinology, and provides a forum of debate of the highest quality on these issues. Journal of Diabetes & Metabolic Disorders is the official journal of the Endocrinology and Metabolism Research Institute, published on behalf of Tehran University of Medical Sciences.
- 2 September 2019
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 19 (1) , 661
Correction to: Exploring the bi-directional relationship between pancreatic cancer and diabetes mellitus: a retrospective study
Please note, we are currently updating the 2018 Journal Metrics. Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of diabetes and endocrinology, and provides a forum of debate of the highest quality on these issues. Journal of Diabetes & Metabolic Disorders is the official journal of the Endocrinology and Metabolism Research Institute, published on behalf of Tehran University of Medical Sciences.
- 15 November 2018
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 17 (2) , 247-252
Exploring the bi-directional relationship between pancreatic cancer and diabetes mellitus: a retrospective study
To explore the bi-directional between pancreatic cancer (PC) and diabetes mellitus (DM); focusing on the prevalence, temporal association and impact on survival outcomes.
- 15 November 2018
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 17 (2) , 247-252
Exploring the bi-directional relationship between pancreatic cancer and diabetes mellitus: a retrospective study
To explore the bi-directional between pancreatic cancer (PC) and diabetes mellitus (DM); focusing on the prevalence, temporal association and impact on survival outcomes.
- 2 July 2018
- Published by Springer Nature in Medical Oncology
- Vol. 35 (8) , 115
Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience
The prognosis of pancreatic cancer remains very poor, with a 5-year survival rate of around 3%. There has been little impact from various chemotherapy regimens on improving outcome for several decades. Gemcitabine has been the mainstay chemotherapy for around two decades with little improvement in overall survival (OS) for patients with advanced disease. However, more recently, there has been a paradigm shift in treatment options for these patients. Reported in 2011, combination therapy with FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) showed a long awaited but modest improvement in survival, but is reserved only for a small proportion of very fit patients due to concerns over its toxicities. In 2013, the landmark phase III international study MPACT demonstrated an improvement in OS with the combination of nab-paclitaxel and gemcitabine (GEMBRAX) for the treatment of patients more akin to the real-world population. In the United Kingdom (UK), it was first made widely available on the National Health Service (NHS) in Wales in September 2014 and only recently received a final positive appraisal by NICE (National Institute of Clinical Excellence) for England in 2017. In this paper, we present our data on the use of this treatment for patients in South Wales and compare real-life practical experience with the MPACT data and reflecting the impact of this paradigm shift.
- 2 July 2018
- Published by Springer Nature in Medical Oncology
- Vol. 35 (8) , 115
Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience
The prognosis of pancreatic cancer remains very poor, with a 5-year survival rate of around 3%. There has been little impact from various chemotherapy regimens on improving outcome for several decades. Gemcitabine has been the mainstay chemotherapy for around two decades with little improvement in overall survival (OS) for patients with advanced disease. However, more recently, there has been a paradigm shift in treatment options for these patients. Reported in 2011, combination therapy with FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) showed a long awaited but modest improvement in survival, but is reserved only for a small proportion of very fit patients due to concerns over its toxicities. In 2013, the landmark phase III international study MPACT demonstrated an improvement in OS with the combination of nab-paclitaxel and gemcitabine (GEMBRAX) for the treatment of patients more akin to the real-world population. In the United Kingdom (UK), it was first made widely available on the National Health Service (NHS) in Wales in September 2014 and only recently received a final positive appraisal by NICE (National Institute of Clinical Excellence) for England in 2017. In this paper, we present our data on the use of this treatment for patients in South Wales and compare real-life practical experience with the MPACT data and reflecting the impact of this paradigm shift.
- 1 January 2015
- Published by Springer Nature
- p. 719-734
Clinical Approaches to the Management of Neuroendocrine Tumours
- 1 January 2015
- Published by Springer Nature
- p. 719-734
Clinical Approaches to the Management of Neuroendocrine Tumours
- 24 July 2012
- Published by Springer Nature in Medical Oncology
- Vol. 29 (5) , 3535-3539
Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma
- 24 July 2012
- Published by Springer Nature in Medical Oncology
- Vol. 29 (5) , 3535-3539
Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma
- Open Access
- 1 July 2012
- Published by Taylor & Francis in Cancer Management and Research
- Vol. 4, 207-14
Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
Peer reviewed article authored by (Yim K-L). Read article or submit your manuscript for publishing.
- 1 July 2012
- Published by Taylor & Francis in Cancer Management and Research
- Vol. 4, 207-14
Open AccessEverolimus and mTOR inhibition in pancreatic neuroendocrine tumors
Peer reviewed article authored by (Yim K-L). Read article or submit your manuscript for publishing.
- 8 September 2011
- Published by Springer Nature in Medical Oncology
- Vol. 29 (3) , 1796-1801
Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome
Approximately 10% of colorectal carcinomas demonstrate microsatellite instability (MSI). Distinct from the majority of colorectal cancers with chromosomal instability (CIN) which harbour allelic imbalance from chromosomal polyploidy and aneuploidy, MSI tumours retain intact chromosomal numbers but contain microsatellite repeats due to deficiency in mismatch repair which are thought to contribute to the early steps of tumourigenesis in colorectal cancer. While emerging clinical data has highlighted improved prognosis of tumours with MSI in early colorectal cancer and potentially circumventing the need for adjuvant chemotherapy, the implications of MSI deficiency in metastatic colorectal cancer (mCRC) remain uncertain. In order to assess the significance of MSI in mCRC, a broad literature review was carried out through online PubMed search on published articles encompassing pathological and clinical papers. This included pathological studies identifying the correlation with MSI status between primary sites and metastases, and chemotherapeutic studies assessing the impact of fluoropyrimidine-, irinotecan- and oxaliplatin-based regimens on mCRC with MSI.
- 8 September 2011
- Published by Springer Nature in Medical Oncology
- Vol. 29 (3) , 1796-1801
Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome
Approximately 10% of colorectal carcinomas demonstrate microsatellite instability (MSI). Distinct from the majority of colorectal cancers with chromosomal instability (CIN) which harbour allelic imbalance from chromosomal polyploidy and aneuploidy, MSI tumours retain intact chromosomal numbers but contain microsatellite repeats due to deficiency in mismatch repair which are thought to contribute to the early steps of tumourigenesis in colorectal cancer. While emerging clinical data has highlighted improved prognosis of tumours with MSI in early colorectal cancer and potentially circumventing the need for adjuvant chemotherapy, the implications of MSI deficiency in metastatic colorectal cancer (mCRC) remain uncertain. In order to assess the significance of MSI in mCRC, a broad literature review was carried out through online PubMed search on published articles encompassing pathological and clinical papers. This included pathological studies identifying the correlation with MSI status between primary sites and metastases, and chemotherapeutic studies assessing the impact of fluoropyrimidine-, irinotecan- and oxaliplatin-based regimens on mCRC with MSI.
- 26 August 2011
- Published by Springer Nature in Endocrine
- Vol. 40 (2) , 181-186
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours
Approximately two-thirds of neuroendocrine tumours (NET) occur in the gastrointestinal tract and over 60% present with metastases. With greater insight into molecular pathways involved in tumour progression, opportunities are presented for the use of targeted therapies in NET. Although a wide array of targeted agents has been investigated, only a handful has emerged as forerunners from recent clinical trials. This literature review focuses on the use of anti-angiogenic monoclonal antibody bevacizumab, as well as small molecule inhibitors sunitinib and everolimus.
- 26 August 2011
- Published by Springer Nature in Endocrine
- Vol. 40 (2) , 181-186
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours
Approximately two-thirds of neuroendocrine tumours (NET) occur in the gastrointestinal tract and over 60% present with metastases. With greater insight into molecular pathways involved in tumour progression, opportunities are presented for the use of targeted therapies in NET. Although a wide array of targeted agents has been investigated, only a handful has emerged as forerunners from recent clinical trials. This literature review focuses on the use of anti-angiogenic monoclonal antibody bevacizumab, as well as small molecule inhibitors sunitinib and everolimus.
- 6 August 2011
- Published by Springer Nature
- Vol. 185, 159-171
Targeted Drug Therapies and Cancer
With the progress of research in molecular biology and greater understanding of cell signalling systems emerge an increasing array of potential targets for the therapy of cancer. While traditional chemotherapy aims to elicit tumour cell death, it also produces undesirable side effects on physiologically proliferating cells. By isolating cell surface receptors which link specific intracellular secondary messenger pathways, researchers are increasingly able to define the biological network which drives cellular function. Of importance are routes involved in malignant transformation, proliferation, survival and angiogenesis. Thus targeted therapy is directed to specific differential growth processes particular to malignant tumours. The principle mode of action generally involves the “lock-and-key” mechanism and identifying the “Achilles’ heel” for drug action. Various targeted agents have been studied and many have translated into significant clinical benefit. This chapter will describe some examples which illustrate the role of this approach in gastrointestinal cancers.
- 6 August 2011
- Published by Springer Nature
- Vol. 185, 159-171
Targeted Drug Therapies and Cancer
With the progress of research in molecular biology and greater understanding of cell signalling systems emerge an increasing array of potential targets for the therapy of cancer. While traditional chemotherapy aims to elicit tumour cell death, it also produces undesirable side effects on physiologically proliferating cells. By isolating cell surface receptors which link specific intracellular secondary messenger pathways, researchers are increasingly able to define the biological network which drives cellular function. Of importance are routes involved in malignant transformation, proliferation, survival and angiogenesis. Thus targeted therapy is directed to specific differential growth processes particular to malignant tumours. The principle mode of action generally involves the “lock-and-key” mechanism and identifying the “Achilles’ heel” for drug action. Various targeted agents have been studied and many have translated into significant clinical benefit. This chapter will describe some examples which illustrate the role of this approach in gastrointestinal cancers.